Aquestive Therapeutics
AQST
45 hedge funds and large institutions have $10.8M invested in Aquestive Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 11 closing their positions.
267% more call options, than puts
Call options by funds: $33K | Put options by funds: $9K
3.63% less ownership
Funds ownership: 37.49% → 33.87% (-3.6%)
12% less funds holding
Funds holding: 51 → 45 (-6)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
73% less capital invested
Capital invested by funds: $40.7M → $10.8M (-$29.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.59M |
| 2 |
Millennium Management
New York
|
+$1.13M |
| 3 |
CAC
Cowen and Company
New York
|
+$166K |
| 4 |
VF
Virtu Financial
New York
|
+$127K |
| 5 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
+$82.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GL
Graypoint LLC
Albany,
New York
|
-$1.08M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$340K |
| 3 |
PP
PDT Partners
New York
|
-$265K |
| 4 |
JP Morgan Chase
New York
|
-$219K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$166K |
AQST Hedge Fund Activity: Q2 2022 in Review
45 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Aquestive Therapeutics (AQST) for Q2 2022, worth a combined $10.8M — down 73% from $40.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of AQST and 5 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 11 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.59M. The largest seller was Graypoint LLC, exiting entirely with an estimated $1.08M sold.
- 45 institutional investors held Aquestive Therapeutics (AQST) as of Q2 2022, down from 51 in Q1 2022.
- Funds reported $10.8M of Aquestive Therapeutics stock for Q2 2022, down 73% quarter-over-quarter.
- 5 funds opened new Aquestive Therapeutics positions in Q2 2022 and 11 closed out, a net change of -6 holders.
- The largest Aquestive Therapeutics buyer in Q2 2022 was Renaissance Technologies, an estimated $1.59M added.
- The largest Aquestive Therapeutics seller in Q2 2022 was Graypoint LLC, an estimated $1.08M sold.
Based on aggregated 13F filings for Q2 2022.